𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease

✍ Scribed by Peter J. Connelly; Neil P. Prentice; Gary Cousland; Jim Bonham

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
87 KB
Volume
23
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objectives

(1) to assess the effect of 1 mg folic acid supplementation of cholinesterase inhibitors (ChI) in a 6 month double‐blind placebo‐controlled study of patients with Alzheimer's Disease (AD) and (2) to assess whether outcome measures were affected by changes in homocysteine levels.

Method

Fifty‐seven consecutive outpatients with probable AD were treated concurrently with a ChI and either folic acid or placebo. None had conditions or medication known to interfere with folate metabolism. Fasting folate and homocysteine levels were measured prior to commencing ChI and 6 months later. Response was categorised using criteria of the National Institute of Clinical Excellence (NICE).

Results

Twelve males and 29 females completed treatment (mean age 76.27 SD 6.23 years, Mini‐Mental State Examination (MMSE) 23.49 SD 3.53, baseline homocysteine 18.39 SD 4.62 micromoles per litre). 23 received folic acid and 18 placebo. There were no significant baseline differences or use of individual ChI between the two arms. After 6 months a significant difference was seen in the change from baseline in combined Instrumental Activities of Daily Living and Social Behaviour scores between arms (folate + 1.50 (SD 5.32) vs placebo −2.29 (SD 6.16) (p = 0.03) but not change in MMSE scores. Sixteen of 23 subjects receiving folic acid and 7/18 placebo subjects were classified as NICE responders (p = 0.05).

Conclusion

This pilot double blind study suggests that response to ChI in patients with AD may be improved by the use of folic acid. The relationship between any change in homocysteine levels and response to treatment is discussed. Copyright © 2007 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

A double-blind, placebo-controlled singl
A double-blind, placebo-controlled single dose trial of intravenous flumazenil in Alzheimer's disease
✍ Lisa Templeton; Andrew Barker; Keith Wesnes; David Wilkinson 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB 👁 2 views

Benzodiazepine agonists have been shown to reduce cognitive functioning by producing attentional de®cits similar to those produced by muscarinic antagonists. It has therefore been postulated that benzodiazepine antagonists may improve cognitive function in patients with Alzheimer's disease by indire

Randomized, placebo-controlled, double-b
Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease
✍ Andrea Martinuzzi; Alexandra Liava; Enrico Trevisi; Mara Frare; Caterina Tonon; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

## Abstract McArdle's disease causes limitation in exercise capacity as well as disability, the severity of which has been associated with the angiotensin‐converting enzyme (ACE) insertion (I)/deletion (D) haplotype—patients with the genotype associated with higher ACE activity show the most severe

Risperidone for psychosis of Alzheimer's
Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial
✍ Henry Brodaty; David Ames; John Snowdon; Michael Woodward; Jeff Kirwan; Roger Cl 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

## Objective: To evaluate the efficacy and safety of low-dose risperidone in treating psychosis of alzheimer's disease (ad) and mixed dementia (md) in a subset of nursing-home residents who had dementia and aggression and who were participating in a randomized placebo-controlled trial of risperidon

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease
✍ J. P. Wright; Dr. D. P. Jewell; R. Modigliani; H. Malchow 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB 👁 2 views

Olsalazine, consisting of two salicylate radicals linked by an azo-bond, is effective in the treatment of active ulcerative colitis. To test its effect in patients with mild to moderate attacks of Crohn's disease, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) des